Furthermore, the findings of a preclinical study examining the efficacy of recombinant human IL-7 (rhIL-7) as a lymphostimulating intervention in sepsis revealed that the ex vivo administration of rhIL-7 to patients’ cells resulted in a noteworthy enhancement of lymphocyte functionality in various aspects, including the proliferation of CD4(+) and CD8(+) lymphocytes, the production of IFN-γ, the phosphorylation of STAT5, and the induction of B cell lymphoma 2 following stimulation (Venet et al., 2012). The gene discussed is IL7; the disease is Sepsis.